PK1 doxorubicin-HPMA conjugate

Known as: PK1 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

DoxorubicinPolymethacrylic Acidsdoxorubicin-HPMA conjugate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Expression and regulation of the prokineticins (endocrine gland-derived vascular endothelial growth factor and Bv8) and their receptors in the human endometrium across the menstrual cycle.
This study investigated the possible role of the newly discovered endocrine gland-derived vascular endothelial growth factors and… (More)
Is this relevant?
2001
2001
Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis.
BACKGROUND Induction of heme oxygenase-1 (HO-1) protects against diverse insults in the kidney and other tissues. We examined the… (More)
  • figure 2
  • figure 4
  • figure 5
  • figure 6
  • figure 7
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Human pancreatic adenocarcinoma cell lines PK1 and PK8 are resistant to the clinically relevant chemotherapy agent gemcitabine… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer…
PK1 comprises doxorubicin covalently bound to N-(2-hydroxypropyl)methacrylamide copolymer by a peptidyl linker. Following… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
 
Is this relevant?
1999
1999
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
PK1 is a synthetic N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin (dox) conjugate currently undergoing Phase II… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
1998
1998
Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1).
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (PK1) is a novel polymeric anticancer agent containing doxorubicin… (More)
Is this relevant?
1998
1998
Apical and basolateral uptake and intracellular fate of dopamine precursor L-dopa in LLC-PK1 cells.
The present study was aimed at the uptake of L-3,4-dihydroxyphenylalanine (L-dopa) and its intracellular decarboxylation to… (More)
Is this relevant?
1994
1994
In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
1. SB 200646A, N-(1-methyl-5-indolyl)-N'-(3-pyridyl) urea hydrochloride, the first reported selective 5-HT2C/2B over 5-HT2A… (More)
Is this relevant?